Balancing Efficacy and Safety: Navigating Dose Adjustments and Therapy Optimization in Myelofibrosis
September 10th 2025Jessica Lewis-Gonzalez, PharmD, BCOP, discusses the management of hematologic and non-hematologic toxicities in cancer patients, emphasizing the importance of proactive monitoring and collaboration between clinicians and pharmacists.
Aficamten Emerges as a Potential First-Line Therapy in Hypertrophic Cardiomyopathy
September 10th 2025Michael Fifer, MD, discusses the Maple HCM study, which compared the cardiac myosin inhibitor Aficamten and the beta blocker Metoprolol in patients with obstructive hypertrophic cardiomyopathy (HCM).
Final Thoughts on Shingles Management
September 9th 2025An expert emphasizes the importance of prompt antiviral treatment and personalized pain management for shingles—particularly in high-risk patients—while highlighting the pharmacist’s role in guiding appropriate over-the-counter care, promoting vaccination through timely conversations, and leveraging tools like immunization registries and word of mouth to improve prevention efforts.
Challenges in Shingles Prevention
September 9th 2025An expert highlights the critical role of vaccination in preventing shingles—especially for high-risk patients with chronic conditions—while addressing challenges like postpandemic vaccine fatigue, emphasizing pharmacists’ unique position to build trust, offer timely education during routine visits, and improve uptake through personalized, visually supported, and seasonally timed conversations.
Expert: Zongertinib Offers Well-Tolerated, Convenient Oral Option for HER2-Mutant NSCLC
September 8th 2025Joshua K. Sabari, MD, explains zongertinib’s (Hernexeos) favorable safety profile and quality-of-life benefits over intravenous antibody-drug conjugates in patients with HER2-mutated non-small cell lung cancer (NSCLC).
Insights: NCCN Adds Zongertinib as Preferred Therapy for HER2-Mutant NSCLC
September 6th 2025Joshua K. Sabari, MD, discusses how zongertinib’s inclusion in the National Comprehensive Care Network (NCCN) guidelines represents a game-changing second-line treatment for HER2-mutant non-small cell lung cancer (NSCLC).
AMCP CEO Raises Concerns Over ACIP Changes, Stresses Pharmacists’ Expanding Public Health Role
September 5th 2025Susan Cantrell, RPh, MHL, CAE, CEO of the Academy of Managed Care Pharmacy (AMCP), warns that politicizing the Advisory Committee on Immunization Practices (ACIP) could undermine vaccine trust.
Expert: APhA Empowers Pharmacists to Tackle Vaccine Hesitancy, Pharmacy Deserts
September 4th 2025Allison Hill, PharmD, RPh, highlights the need for pharmacists to leverage resources, collaborate with other providers, advocate on social media, and support rural communities with limited access to care.
A Pharmacist’s View of Emerging CML Treatment
September 4th 2025A panelist discusses how emerging chronic myeloid leukemia treatment advancements, including the addition of asciminib as a frontline tyrosine kinase inhibitor (TKI) option and ongoing research into dual TKI therapy and optimal dosing strategies, are expanding therapeutic choices while pharmacists play a key role in educating patients and providers about evolving treatment algorithms, evaluating new literature, and helping teams manage newer agents with less clinical experience.
Potential for Precision: Exploring Targeted Therapies in mCRC Care
September 4th 2025Panelists discuss how the importance of having pharmacists embedded in oncology clinics has transformed metastatic colorectal cancer care by enabling real-time decision-making and dose adjustments, while highlighting that these are exciting times with multiple new oral treatment options that patients often prefer over infusions, though managing adherence and side effects remains challenging, and emphasizing that current targeted therapy opportunities include rare but actionable NTRK fusions, HER2 amplifications (3% of cases with multiple treatment options), and KRAS G12C mutations (3% of cases), with future promise in pan-RAS inhibitors, expanded immunotherapy beyond MSI-high tumors, and combination therapies, though dermatologic toxicity from targeted agents like RAS inhibitors will likely be the rate-limiting factor requiring better assessment tools and multidisciplinary management including dermatology support.
Empowering Pharmacists in the Management of Patients With Urothelial Cancer
September 3rd 2025Sherry Vogt, PharmD, BCOP; and Megan Hinkley, PharmD, MBA, BCOP, discuss how pharmacists play a crucial role in managing patients with bladder cancer through treatment selection, patient education, adverse effect monitoring, and the evolving landscape of therapies including traditional chemotherapy, immunotherapy, and antibody-drug conjugates like enfortumab vedotin plus pembrolizumab.
CMS Mailing Restrictions and Their Impact on Oncology Care Delivery
September 3rd 2025David Eagle, MD, Chair of Legislative Affairs and Patient Advocacy, explains how CMS’s ban on community oncology practices mailing medications creates inequities with PBMs and adds burdens for vulnerable cancer patients.
Expert: ECAPS Act Could Sustain Pharmacists’ Public Health Role Postpandemic
September 2nd 2025Susan Cantrell, RPh, MHL, CAE, highlights the Equitable Community Access to Pharmacy Services (ECAPS) Act as the top federal priority to preserve pharmacists’ authority in testing, treatment, and immunization services.
Risk Factors and Complications Associated With Shingles
September 2nd 2025An expert discusses strategies for educating patients about the serious, long-term complications of shingles by using vivid, relatable language and real-life examples—emphasizing the disabling nature of postherpetic neuralgia, leveraging personal stories to increase vaccine receptivity, and reframing shingles as a pain condition rather than just a rash to prompt more meaningful prevention conversations.
Best Practices for Educating Patients About Shingles
September 2nd 2025An expert discusses how to effectively engage patients in conversations about the shingles vaccine by using visual aids, clarifying misconceptions, and personalizing education based on timing and health status; they emphasize the importance of setting realistic expectations about adverse effects, identifying high-risk individuals through prescription history, and leveraging pharmacists’ regular contact with patients to drive timely, impactful vaccine recommendations.
Empowering Pharmacists in the Management of Patients With Urothelial Cancer
September 1st 2025Sherry Vogt, PharmD, BCOP; and Megan Hinkley, PharmD, MBA, BCOP, discuss how pharmacists play a crucial role in managing patients with bladder cancer through treatment selection, patient education, adverse effect monitoring, and the evolving landscape of therapies including traditional chemotherapy, immunotherapy, and antibody-drug conjugates like enfortumab vedotin plus pembrolizumab.
AMCP CEO: Pharmacists’ Communication, Trust-Building Key to Addressing Vaccine Hesitancy
August 31st 2025Susan Cantrell, RPh, MHL, CAE, CEO of the Academy of Managed Care Pharmacy, stresses the importance of listening, empathy, and science-based communication in pharmacists’ efforts to guide patients through vaccine decisions.